Abstract
Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1508-1512 |
| Number of pages | 5 |
| Journal | JAMA Internal Medicine |
| Volume | 177 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
Cite this
Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome : A value-based quality improvement. / Alvin, Matthew D.; Jaffe, Allan S; Ziegelstein, Roy C.; Trost, Jeffrey C.
In: JAMA Internal Medicine, Vol. 177, No. 10, 01.10.2017, p. 1508-1512.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome
T2 - A value-based quality improvement
AU - Alvin, Matthew D.
AU - Jaffe, Allan S
AU - Ziegelstein, Roy C.
AU - Trost, Jeffrey C.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.
AB - Cardiac biomarker testing is estimated to occur in nearly 30 million emergency department visits nationwide each year in the United States. The American College of Cardiology/ European Society of Cardiology indicate that cardiac troponin is the biomarker of choice owing to its nearly absolute myocardial tissue specificity and high clinical sensitivity for myocardial injury. Multiple academic medical centers have implemented interventions to eliminate the routine ordering of creatine kinase–myocardial band tests, with published patient safety outcomes data; however, creatine kinase–myocardial band testing is still ordered in many hospitals and emergency departments. Eliminating a simple laboratory test that provides no incremental value to patient care can lead to millions of health care dollars saved without adversely affecting patient care quality, and in this case potentially improving patient care.
UR - http://www.scopus.com/inward/record.url?scp=85030977750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030977750&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2017.3597
DO - 10.1001/jamainternmed.2017.3597
M3 - Article
C2 - 28806444
AN - SCOPUS:85030977750
VL - 177
SP - 1508
EP - 1512
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 10
ER -